Conversation with The Cancer Letter

Conversation with The Cancer Letter

FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials
Conversation with The Cancer Letter

FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials

The past six weeks have brought fundamental change in the way oncology drugs are being developed. At this unprecedented moment in oncopolitics, FDA, NCI, academic oncologists, advocates, and the industry are in agreement on how cancer therapies should be developed, tested and approved.
By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer
Conversation with The Cancer Letter

Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer
Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

Patients with metastatic non-small cell lung cancer who are matched to targeted therapy live longer when liquid biopsies are used to detect genomic alterations in circulating tumor DNA that aren’t picked up by tissue sequencing, according to a study published Nov. 10 in Nature Medicine.
By Matthew Bin Han Ong
NCI’s Doroshow: “These recommendations are something that we can implement right away”
Conversation with The Cancer Letter

NCI’s Doroshow: “These recommendations are something that we can implement right away”

NCI will immediately start the process of streamlining IND-exempt trials in order to make them faster, simpler, more flexible, less expensive, and easier to integrate with clinical practice, James Doroshow, NCI deputy director for clinical and translational research and director of the Division of Cancer Treatment and Diagnosis, said to The Cancer Letter. On Nov. […]
By Paul Goldberg